These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23669414)

  • 41. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy.
    Rowan PJ; Al-Jurdi R; Tavakoli-Tabasi S; Kunik ME; Satrom SL; El-Serag HB
    J Clin Gastroenterol; 2005 Sep; 39(8):731-6. PubMed ID: 16082286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.
    Groessl EJ; Liu L; Sklar M; Ho SB
    Int J Hepatol; 2017; 2017():5834182. PubMed ID: 28819570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C.
    Rowan PJ; Tabasi S; Abdul-Latif M; Kunik ME; El-Serag HB
    J Clin Gastroenterol; 2004 Jul; 38(6):530-4. PubMed ID: 15220690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.
    Beste LA; Ioannou GN
    Epidemiol Rev; 2015; 37():131-43. PubMed ID: 25600415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary care provider perceptions and experiences of implementing hepatitis C virus birth cohort testing: a qualitative formative evaluation.
    Yakovchenko V; Bolton RE; Drainoni ML; Gifford AL
    BMC Health Serv Res; 2019 Apr; 19(1):236. PubMed ID: 31014322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy.
    George N; Harrell SM; Rhodes KD; Duarte-Rojo A
    Ann Hepatol; 2018; 17(1):76-84. PubMed ID: 29311404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    Evon DM; Stewart PW; Amador J; Serper M; Lok AS; Sterling RK; Sarkar S; Golin CE; Reeve BB; Nelson DR; Reau N; Lim JK; Reddy KR; Di Bisceglie AM; Fried MW
    PLoS One; 2018; 13(8):e0196908. PubMed ID: 30067745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
    Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
    Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration.
    Maier MM; Ross DB; Chartier M; Belperio PS; Backus LI
    Am J Public Health; 2016 Feb; 106(2):353-8. PubMed ID: 26562129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.
    Dever JB; Ducom JH; Ma A; Nguyen J; Liu L; Herrin A; Groessl EJ; Ho SB
    Dig Dis Sci; 2017 Jun; 62(6):1472-1479. PubMed ID: 28378246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program.
    Burton MJ; Voluse AC; Anthony V
    J Subst Abuse Treat; 2019 Mar; 98():9-14. PubMed ID: 30665610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.
    Bonner JE; Barritt AS; Fried MW; Evon DM
    Dig Dis Sci; 2012 Jun; 57(6):1469-74. PubMed ID: 22484494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C management by addiction medicine physicians: results from a national survey.
    Litwin AH; Kunins HV; Berg KM; Federman AD; Heavner KK; Gourevitch MN; Arnsten JH
    J Subst Abuse Treat; 2007 Jul; 33(1):99-105. PubMed ID: 17379472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Management of hepatitis C among drug user patients].
    Moussalli J; Melin P; Wartelle-Bladou C; Lang JP
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S51-5. PubMed ID: 17965636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.
    Evon DM; Simpson K; Kixmiller S; Galanko J; Dougherty K; Golin C; Fried MW
    Am J Gastroenterol; 2011 Oct; 106(10):1777-86. PubMed ID: 21769136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984.
    Kielland KB; Amundsen EJ; Dalgard O
    Scand J Gastroenterol; 2014 Dec; 49(12):1465-72. PubMed ID: 25310139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.
    Belperio PS; Chartier M; Ross DB; Alaigh P; Shulkin D
    Ann Intern Med; 2017 Oct; 167(7):499-504. PubMed ID: 28973196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expanding the Scope of Integrated Behavioral Health Care for Patients With Hepatitis C Virus.
    Pyne JM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):2015-6. PubMed ID: 25952310
    [No Abstract]   [Full Text] [Related]  

  • 59. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
    Loftis JM; Matthews AM; Hauser P
    Drugs; 2006; 66(2):155-74. PubMed ID: 16451091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C.
    Chirikov VV; Shaya FT; Mullins CD; dosReis S; Onukwugha E; Howell CD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1447-62. PubMed ID: 26524244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.